7th Dec 2007 12:00
Basingstoke, UK and Philadelphia, US - December, 07 2007 - Shire plc
Notification of major interests in shares
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
2. Reason for the notification State Yes/No An acquisition or disposal of voting rights Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights
Other (please specify): New Exemption DTR 5.1.3 (4) & DTR 5.1.5 Yes (1)
3. Full name of person(s) subject to the notification obligation: The Goldman Sachs Group Inc 4. Full name of shareholder(s) (if different from 3.): Goldman, Sachs & Co.
5. Date of the transaction (and date on which the threshold is 04 December crossed
2007 or reached if different): 6. Date on which issuer notified: 06 December 2007 7. Threshold(s) that is/are crossed or reached: Below 3% 8. Notified details:
A: Voting rights attached to shares
Class/type of Situation previous to Resulting situation after the triggering
shares the Triggering transaction if possible transaction
using the ISIN CODE Number Number Number Number of voting % of voting of of of rights rights Shares Voting shares Rights Direct Direct Indirect Direct Indirect GB00B0KQX869 1,929,050 0.35% US82481R1068 15,656,661 2.80% (5,218,887ADRs)
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting % of financial date Conversion rights that may be voting instrument Period/ Date acquired if the rights instrument is exercised/converted Total (A+B) Number of voting rights % of voting rights Below 3%
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
We hereby notify you that as at close of business on 04 December 2007 the Goldman Sachs Group, Inc., of 85 Broad Street, New York, NY 10004, USA, no longer has a notifiable interest in shares.
Proxy Voting:10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting N/A
rights: 13. Additional information: General Email Contact: [email protected] 14. Contact name: Sean Rogers/Alex Cox
15. Contact telephone number: 44(20)7552-9205/ 44(20)774-8774
(Contact at Shire plc: Phil Griffin-Smith, Interim Deputy Company Secretary, 01256 894754)
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release
Registered in England 5492592Registered Office as above
SHIRE PLCRelated Shares:
Shire